DAX20.754 +5,5%ESt504.878 +5,5%Top 10 Crypto10,99 -1,9%Dow40.608 +7,9%Nas17.125 +12,2%Bitcoin73.680 -2,3%Euro1,1039 +0,8%Öl63,23 -3,8%Gold3.107 +0,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Tesla A1CX3T Apple 865985 Amazon 906866 RENK RENK73 Allianz 840400 Mercedes-Benz Group (ex Daimler) 710000 Infineon 623100 Volkswagen (VW) vz. 766403 Lufthansa 823212 BASF BASF11 Microsoft 870747 Deutsche Telekom 555750 Deutsche Bank 514000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Trump lenkt im Handelskrieg ein: DAX mit Kurssprung -- Asiens Börsen schließen deutlich höher -- VW verdient weniger als erwartet -- Bankaktien, TSMC, Nordex im Blick
Top News
Die besten Tagesgeld-Zinsen: Welche Banken führen den Vergleich an? Die besten Tagesgeld-Zinsen: Welche Banken führen den Vergleich an?
Apple-Aktie mit stärkstem Kursplus seit Januar 1998 - doch China-Sorgen bleiben Apple-Aktie mit stärkstem Kursplus seit Januar 1998 - doch China-Sorgen bleiben
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Alvotech Registered Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
7,94 EUR +0,88 EUR +12,46 %
FSE
8,72 USD +0,65 USD +8,05 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.2,40 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3DK8U

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINLU2458332611

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolALVO

Alvotech Registered Aktien News

DatumMeistgelesen
GlobeNewswireAlvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
GlobeNewswireAlvotech Reports Record Results for 2024 and Provides Business Update
GlobeNewswireUK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
Wer­bungAlvotech Registered-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
GlobeNewswireAlvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
GlobeNewswireAlvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
GlobeNewswireAlvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida
GlobeNewswireAlvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET
GlobeNewswireTeva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
GlobeNewswireAlvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
GlobeNewswireAlvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
GlobeNewswireAlvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
GlobeNewswireAlvotech Reports Financial Results for the First Nine Months of 2024
GlobeNewswireAlvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
GlobeNewswireEuropean Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
GlobeNewswireAlvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
GlobeNewswireAlvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
GlobeNewswireAlvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (us
GlobeNewswireEuropean Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
GlobeNewswireAlvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®
GlobeNewswireAlvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
GlobeNewswireAlvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
GlobeNewswireEuropean Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
GlobeNewswireAlvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
GlobeNewswireSTADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
GlobeNewswireAlvotech Announces Closing of Private Debt Financing
GlobeNewswireAlvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
GlobeNewswireAlvotech Issues New Shares to Holders of Convertible Bonds
GlobeNewswireAlvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
GlobeNewswireAlvotech Receives Conversion Notices for Majority of Convertible Bonds
GlobeNewswireAlvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
GlobeNewswireAlvotech and STADA add to Strategic Alliance through Denosumab Partnership
GlobeNewswireAlvotech Announces Strategic Refinancing Agreement
GlobeNewswireAlvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
GlobeNewswireAlvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswireAlvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
GlobeNewswireTeva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
GlobeNewswireAlvotech S.A. Annual General Meeting to be held June 7, 2024
GlobeNewswireAlvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
GlobeNewswireAlvotech Announces Participation at BofA Securities Healthcare Conference 2024
GlobeNewswireU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
Wer­bung

Alvotech Registered News

Alvotech Registered News: auf dieser Seite finden Sie alle Alvotech Registered News und Nachrichten zur Alvotech Registered Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Alvotech Registered News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Alvotech Registered News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.